Takeda Pharmaceutical (TAK) EBITDA Margin (2017 - 2026)

Takeda Pharmaceutical's EBITDA Margin history runs 10 years deep, the most recent figure standing at 38.02% for Q1 2026.

• On a quarterly basis, EBITDA Margin fell 5330.0% year-over-year to 38.02% in Q1 2026; TTM through Mar 2026 was 2.64%, a 1255.0% decrease from a year earlier, with the FY2026 full-year figure at 0.14%, down 734.0% from the prior year.
• EBITDA Margin held at 38.02% in Q1 2026 per TAK's latest filing, from 38.03% in the prior quarter.
• Across five years, EBITDA Margin topped out at 25.56% in Q1 2022 and bottomed at 38.03% in Q4 2025.
• The 5-year median for EBITDA Margin is 13.4% (2022), against an average of 6.88%.
• Across the five-year window, EBITDA Margin jumped 602 bps in 2022 and plunged 5330 bps in 2026, its largest moves.
• Year by year, EBITDA Margin stood at 13.4% in 2022, then slumped by 37 bps to 8.43% in 2023, then sank by 184 bps to 7.11% in 2024, then plunged by 435 bps to 38.03% in 2025, then grew by 0 bps to 38.02% in 2026.
• Per Business Quant, the three latest TAK EBITDA Margin figures stand at 38.02% (Q1 2026), 38.03% (Q4 2025), and 11.97% (Q3 2025).